# Illumina (ILMN) Q2 FY2026 earnings

Results filed 2026-07-30 for the quarter ended 2026-06-28. Source page: https://earnings.opennash.com/companies/ilmn/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000155/0001110803-26-000155-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Illumina's NovaSeq X demand stayed high with more than 95 placements, while clinical customers expanded sequencing use and the company added spatial and multiomics offerings.

Clinical customers drove the quarter, as Illumina says its technology is letting them expand sequencing-intensive applications. NovaSeq X demand stayed high more than three years after launch, with more than 95 placements. Clinical markets make up approximately 65% of sequencing consumables revenue. This summer Illumina launched StrataMap Spatial, a sequencing-based spatial workflow, and biopharma interest is growing with over 300 million cells delivered to date.
Management is steering Illumina toward a broader multiomics ecosystem built on NovaSeq X, with a strategy of delivering the highest quality insights at the lowest end-to-end cost. The tension is execution and cost. Integrating the SomaLogic business and managing proteomics partners is a stated risk, supply investments carry real costs that Illumina is partly sharing with customers, and its place on China's Unreliable Entities List and U.S. tariffs add uncertainty.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $1.16 billion | up 9.5% from Q2 2025 | GAAP |
| Net income | $207 | from $235 in Q2 2025 | GAAP |
| Diluted EPS | $1.35 | from $1.49 in Q2 2025 | GAAP |
| Diluted EPS | $1.31 | from $1.19 in Q2 2025 | non-GAAP |
| Gross margin | 66.4% | from 65.6% in Q2 2025 | GAAP |
| Gross margin | 68.2% | from 69.4% in Q2 2025 | non-GAAP |
| Operating income | $245 | from $214 in Q2 2025 | GAAP |
| Operating margin | 21.1% | from 20.2% in Q2 2025 | GAAP |
| Operating margin | 22.5% | from 23.8% in Q2 2025 | non-GAAP |
| Cash flow from operations | $201 million | compared to $234 million in the prior year period | GAAP |
| Free cash flow | $162 million | compared to $204 million in the prior year period | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Product revenue | $982 | from $912 in Q2 2025 |
| Service and other revenue | 177 | from 147 in Q2 2025 |
| ROW organic revenue growth | 8.1% | excludes currency, acquisitions and China |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Total revenue | fiscal year 2026 | $4.60-$4.64 billion |
| ROW organic revenue growth | fiscal year 2026 | greater than 5% |
| Non-GAAP operating margin | fiscal year 2026 | 23.4%-23.6% |
| Non-GAAP diluted EPS | fiscal year 2026 | $5.30-$5.40 |

## Key takeaways

1. **NovaSeq X demand remains high after three years** More than 95 NovaSeq X placements in the quarter show demand holding well beyond launch. Management says this demand continues as it expands workflow and multiomics capabilities.
2. **Clinical customers are the main growth engine** Clinical markets, about 65% of sequencing consumables revenue, remained the primary growth driver. Management says its technology lets clinical customers expand sequencing-intensive applications.
3. **StrataMap Spatial extends Illumina into spatial biology** Illumina launched StrataMap Spatial, a sequencing-based spatial workflow, this summer. With over 300 million cells delivered to date, biopharma interest continues to grow.
4. **Multiomics is the second leg of strategy** Management frames the strategy as the highest quality insights at the lowest end-to-end cost, with multiomics as the next step. The release points to the SomaLogic business and proteomics as part of that push.
5. **Supply investments are rising and costs are shared** Illumina made significant progress on supply investments in the quarter. Management says those costs are real and that it is sharing some of the increase with customers.

## Questions

**How is NovaSeq X demand holding up?** Demand remained high more than three years after launch, with more than 95 placements in the quarter. The CEO said demand remains high as Illumina expands its workflow and multiomics capabilities.
**Who is driving Illumina's growth?** Clinical markets, approximately 65% of sequencing consumables revenue, were the primary growth driver. Illumina says its technology is enabling clinical customers to expand sequencing-intensive applications.
**What did Illumina launch this quarter?** Illumina launched StrataMap Spatial this summer, a sequencing-based spatial workflow. Over 300 million cells have been delivered to date and biopharma interest continues to grow.
**What is Illumina's strategy beyond sequencing?** Its strategy is to deliver the highest quality insights for the lowest end-to-end cost, with a push into multiomics. The release also names integrating the SomaLogic business as a key factor.
**What are the main risks to Illumina's plans?** The release cites SomaLogic integration, proteomics partner and customer relationships, tariffs, and its inclusion on China's Unreliable Entities List. Supply investment costs are also real, and Illumina is sharing some with customers.

